ClinicalTrials.gg
CompletedNCT02131636Updated Nov 18, 2019Results posted

Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea

A Phase 3 interventional study of AGN-199201 and Vehicle to AGN-199201 in Erythema and Rosacea, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Erythema with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Erythema · United States.

Enrollment
2nd of 52
440 · median 52
Started
2014
with 5 others
Phase 3
5 of 55
none open now
Registered
16th of 55
by date
Lead sponsor
7 of 55
Allergan

Among the 55 studies in Erythema with a site in United States, this one is the 2nd largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2014, is one of 5 in phase 3, and was the 16th registered.

Erythema

131 studies on the registry are indexed under Erythema; 17 are open to participants now.

Browse Erythema studies →

Open to participants now

8 of the 55 studies in Erythema with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Erythema studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Erythema with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

03

Conditions studied

  • Erythema
  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Moderate to severe persistent facial erythema associated with rosacea.

Exclusion criteria

Exclusion Criteria:

  • Greater than 3 inflammatory lesions on the face
  • Current treatment with monoamine oxidase (MAO) inhibitors
  • Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    AGN-199201

    AGN-199201 applied to the face once daily for 29 days.

    Drug: AGN-199201

  • Placebo comparator
    Vehicle

    Vehicle to AGN-199201 applied to the face once daily for 29 days.

    Drug: Vehicle to AGN-199201

Interventions

  • AGN-199201 applied to the face once daily for 29 days.

  • DrugVehicle to AGN-199201

    Vehicle to AGN-199201 applied to the face once daily for 29 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales

    The investigator assessed the patient's overall severity of erythema in the treatment area on the 5 point CEA scale (ranging from 0=clear skin with no signs of erythema to 4=severe erythema/fiery redness). The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) on both CEA and SSA from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.

    Time frame: Baseline, Day 29 (Hours 3, 6, 9, and 12)

Secondary outcomes

  1. Percentage of Patients With at Least a 2-Grade Decrease From Baseline on the SSA 5-point Scale

    The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.

    Time frame: Baseline, Day 29 (Hours 3, 6, 9, and 12)

  2. Percent Change From Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA)

    Rosacea facial redness in the treatment area was measured by DIA. The percent change was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. Baseline was defined as the measurement at predose on Day 1. A negative number change from baseline indicates a decrease in facial redness (improvement), and a positive number change from baseline indicates an increase in facial redness (worsening).

    Time frame: Baseline, Day 29 (Hours 3, 6, 9, and 12)

  3. Percentage of Patients Reporting Treatment Satisfaction on the Satisfaction Assessment for Rosacea Facial Redness (SA-RFR) Questionnaire Item 9

    The SA-RFR questionnaire item 9 is completed by patients assessing treatment satisfaction on facial redness. Patients reporting treatment satisfaction as "very satisfied" or "satisfied" are noted. The percentage of patients was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29.

    Time frame: Day 29 (Hours 3, 6, 9, and 12)

  4. Change From Baseline on the SA-RFR Questionnaire Item #4

    The SA-RFR questionnaire item 4 is completed by patients assessing how much their face burned due to facial redness on a 5 point scale (range 0=does not burn at all and 4=burns a lot). Patients were evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. A lower score change from baseline (negative number) indicates a decrease in facial redness (improvement), and a higher score change from baseline (positive number) indicates an increase in facial burning (worsening).

    Time frame: Baseline, Day 29 (Hours 3, 6, 9, and 12)

  5. Percentage of Patients With at Least a 1-Grade Decrease From Baseline on the SSA 5-point Scale

    The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 1 grade decrease (improvement) on the SSA from baseline at Day 1 hour 1. Baseline was defined as the measurement at predose on Day 1.

    Time frame: Baseline, Day 1 (Hour 1)

07

Results

Posted Mar 10, 2016

Participant flow

Participant flow — Overall Study
MilestoneAGN-199201Vehicle
Started222218
Completed210213
Not completed125
Withdrew: Personal reasons44
Withdrew: Lost to follow-up40
Withdrew: Adverse event41

Outcome measures

PrimaryPercentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales

The investigator assessed the patient's overall severity of erythema in the treatment area on the 5 point CEA scale (ranging from 0=clear skin with no signs of erythema to 4=severe erythema/fiery redness). The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) on both CEA and SSA from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.

Time frame:
Baseline, Day 29 (Hours 3, 6, 9, and 12)
Reported as:
Number · Percentage of Patients
Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales
Percentage of PatientsAGN-199201Vehicle
Day 29, Hour 3 (N=222, 216)11.95.5
Day 29, Hour 6 (N=222, 216)15.58.3
Day 29, Hour 9 (N=222, 216)17.76.0
Day 29, Hour 12 (N=222, 216)14.86.0
SecondaryPercentage of Patients With at Least a 2-Grade Decrease From Baseline on the SSA 5-point Scale

The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.

Time frame:
Baseline, Day 29 (Hours 3, 6, 9, and 12)
Reported as:
Number · Percentage of Patients
Percentage of Patients With at Least a 2-Grade Decrease From Baseline on the SSA 5-point Scale
Percentage of PatientsAGN-199201Vehicle
Day 29, Hour 320.111.1
Day 29, Hour 623.312.9
Day 29, Hour 923.312.0
Day 29, Hour 1225.011.5
SecondaryPercent Change From Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA)

Rosacea facial redness in the treatment area was measured by DIA. The percent change was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. Baseline was defined as the measurement at predose on Day 1. A negative number change from baseline indicates a decrease in facial redness (improvement), and a positive number change from baseline indicates an increase in facial redness (worsening).

Time frame:
Baseline, Day 29 (Hours 3, 6, 9, and 12)
Reported as:
Mean · Percent Change
Percent Change From Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA)
Percent ChangeAGN-199201Vehicle
Day 29, Hour 3-21.37 ± 94.69361.54 ± 428.943
Day 29, Hour 6-14.22 ± 97.83575.09 ± 498.844
Day 29, Hour 9-8.00 ± 92.89371.18 ± 398.072
Day 29, Hour 12-5.35 ± 98.54774.16 ± 415.301
SecondaryPercentage of Patients Reporting Treatment Satisfaction on the Satisfaction Assessment for Rosacea Facial Redness (SA-RFR) Questionnaire Item 9

The SA-RFR questionnaire item 9 is completed by patients assessing treatment satisfaction on facial redness. Patients reporting treatment satisfaction as "very satisfied" or "satisfied" are noted. The percentage of patients was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29.

Time frame:
Day 29 (Hours 3, 6, 9, and 12)
Reported as:
Number · Percentage of Patients
Percentage of Patients Reporting Treatment Satisfaction on the Satisfaction Assessment for Rosacea Facial Redness (SA-RFR) Questionnaire Item 9
Percentage of PatientsAGN-199201Vehicle
Day 29, Hour 345.927.5
Day 29, Hour 643.724.3
Day 29, Hour 943.223.4
Day 29, Hour 1241.924.8
SecondaryChange From Baseline on the SA-RFR Questionnaire Item #4

The SA-RFR questionnaire item 4 is completed by patients assessing how much their face burned due to facial redness on a 5 point scale (range 0=does not burn at all and 4=burns a lot). Patients were evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. A lower score change from baseline (negative number) indicates a decrease in facial redness (improvement), and a higher score change from baseline (positive number) indicates an increase in facial burning (worsening).

Time frame:
Baseline, Day 29 (Hours 3, 6, 9, and 12)
Reported as:
Mean · Scores on a Scale
Change From Baseline on the SA-RFR Questionnaire Item #4
Scores on a ScaleAGN-199201Vehicle
Baseline1.8 ± 0.831.9 ± 0.85
Day 29, Hour 3-1.5 ± 0.93-1.5 ± 0.95
Day 29, Hour 6-1.5 ± 0.91-1.5 ± 0.98
Day 29, Hour 9-1.5 ± 0.97-1.5 ± 0.96
Day 29, Hour 12-1.5 ± 0.97-1.5 ± 0.95
SecondaryPercentage of Patients With at Least a 1-Grade Decrease From Baseline on the SSA 5-point Scale

The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 1 grade decrease (improvement) on the SSA from baseline at Day 1 hour 1. Baseline was defined as the measurement at predose on Day 1.

Time frame:
Baseline, Day 1 (Hour 1)
Reported as:
Number · Percentage of Pateints
Percentage of Patients With at Least a 1-Grade Decrease From Baseline on the SSA 5-point Scale
Percentage of PateintsAGN-199201Vehicle
Percentage of Patients With at Least a 1-Grade Decrease From Baseline on the SSA 5-point Scale30.217.4

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AGN-199201—1/222 (0.5%)0/222 (0%)
Vehicle—3/218 (1.4%)0/218 (0%)
Most frequent serious events
Most frequent serious events
EventAGN-199201Vehicle
Atrial FibrillationCardiac disorders0/2221/218
Cardiac FailureCardiac disorders0/2221/218
ArteriosclerosisCardiac disorders0/2221/218
PneumoniaRespiratory, thoracic and mediastinal disorders0/2221/218
FallGeneral disorders1/2220/218

Baseline characteristics

Age, Customized
Age, Customized(Participants)AGN-199201VehicleTotal
18 to 64 years189194383
>=65 years332457
Sex: Female, Male
Sex: Female, Male(Participants)AGN-199201VehicleTotal
Female172175347
Male504393
08

Study locations

1 site
  • Lynchburg, Virginia, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2014
First posted
May 6, 2014
Start
May 2014
Primary completionActual
Nov 2014
CompletionActual
Dec 2014
Results first posted
Mar 10, 2016
Last update
Nov 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02131636
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
May 6, 2014
Start date
May 2014
Primary completion
Nov 2014
Completion
Dec 2014
Results posted
Mar 10, 2016
Last update
Nov 18, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxymetazoline

Start the discussion